Ardelyx, Inc. (ARDX)

1.17
0.01 1.30
NASDAQ
Prev Close 1.15
Open 1.14
Day Low/High 1.14 / 1.17
52 Wk Low/High 1.01 / 9.23
Volume 854.74K
Exchange NASDAQ
Shares Outstanding 103.12B
Market Cap 119.62M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

A Trifecta of Bad News Makes for a Rough Day for This Biotech Investor

A Trifecta of Bad News Makes for a Rough Day for This Biotech Investor

Shares of Cara Therapeutics, Adverum Biotechnologies and Ardelyx Inc. all took big hits after each company announced unfavorable developments.

2 Small-Caps Still Worth Considering in This Red-Hot Market

2 Small-Caps Still Worth Considering in This Red-Hot Market

Oncology concern Exelixis and biopharma Ardelyx offer reasons to believe their shares should rise in the months ahead.

These 3 Biotechs Have Decent Values

These 3 Biotechs Have Decent Values

One would need to use covered calls to initiate positions that provide a solid amount of downside protection.

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.

Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers

Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers

The South San Francisco, Calif.-based firm said its Phase 3 study of tirasemtiv in patients with amyotrophic lateral sclerosis did not achieve primary or secondary endpoints.

Abeona Shares Higher After Pricing Stock Offering -- Biotech Movers

Abeona Shares Higher After Pricing Stock Offering -- Biotech Movers

The clinical-stage biopharmaceutical firm said Oct. 16 it has priced an underwritten public offering of five million shares at $16 apiece.

This Market Action Is Not Creating Many Setups

This Market Action Is Not Creating Many Setups

Until market conditions shift, I won't be making any sizable buys.

Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers

Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers

The Fremont, Calif.-based firm has unveiled positive results from its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Ardelyx Has Big Potential

Ardelyx Has Big Potential

This small-cap company's shares are half where they ended 2015.

Profiting on Small-Cap Biotech Earnings

Profiting on Small-Cap Biotech Earnings

Don't trade the headline numbers, but cash in on those traders that do.